Tolerability, pharmacodynamics and preliminary efficacy of prasugrel in patients with sickle cell disease

Trial Profile

Tolerability, pharmacodynamics and preliminary efficacy of prasugrel in patients with sickle cell disease

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2011

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Embolism and thrombosis; Pain; Sickle cell anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2011 New trial record
    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top